News

In the search for biomarkers of premature birth, EVs are showing promise. EVs are released by all cells, including those of the placenta, allowing for peripheral sampling of placental biomarkers. EVs also protect their cargo which is delivered to target cells, providing a source

NX Prenatal Inc. has been selected as an awardee of the Maternal-fetal Immune Disorders QuickFire Challenge: Innovating for Health Equity. Launched by Johnson & Johnson Innovation in collaboration with the Office of the Chief Medical Officer of The Johnson & Johnson Family of Companies (OCMO) Health of Women team, together with The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), the QuickFire Challenge award will include grant funding and mentorship from experts to help catalyze innovations directed toward the prevention of adverse pregnancy outcomes.

NX Prenatal Inc. announced today that it is a sponsor and collaborator for an upcoming clinical study whereby its NeXosome® liquid biopsy platform will be key in the detection of biomarkers that can identify pregnant patients with Placenta Accreta Spectrum (PAS).

NX Prenatal Inc. today announced that it has achieved new patent issuances in both the United States and Europe for its exosome-based liquid biopsy tests for the early identification of pregnant mothers at elevated risk for spontaneous preterm birth. NX Prenatal controls worldwide rights to a portfolio of more than three dozen pending and issued patents that feature the earliest and most comprehensive claims related to the utilization of exosomes for the detection and management of adverse pregnancy outcomes.

NX Prenatal Inc. today announced the publication of new data demonstrating that exosome-associated protein biomarkers derived from first trimester maternal plasma are key in predicting the overall risk of developing Preeclampsia, and further indicate the ability to identify distinct subtypes of pathophysiology and predict severity of clinical presentation among Preeclampsia patients. The peer-reviewed study of asymptomatic pregnant subjects was published in Scientific Reports and was conducted together with Brigham and Women’s Hospital and Thermo Fisher Scientific.

NX Prenatal Inc. (“NX Prenatal”) and Thermo Fisher Scientific have announced a strategic collaboration designed to expand upon integrated workflows that the companies have established to enable high volume clinical mass spec proteomic evaluation of plasma samples enriched for exosomes via the NeXosome® platform.